ProCE Banner Activity

CE / CME

Choosing Among GLP-1 Receptor Agonists for Patients With Type 2 Diabetes

Tool
Access expert recommendations for GLP-1 receptor agonist therapy for patients with type 2 diabetes.

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Nurses: 0.25 Nursing contact hour

Released: February 26, 2020

Expiration: February 25, 2021

No longer available for credit.

Share

Faculty

Martin J Abrahamson

Martin J Abrahamson, MD, FACP

Associate Professor of Medicine
Harvard Medical School
Director, Division of CME
Department of Medicine
Beth Israel Deaconess Medical Center
Boston, Massachusetts

Zachary T. Bloomgarden

Zachary T. Bloomgarden, MD, MACE

Clinical Professor
Division of Endocrinology
Department of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York

Linda R. Duska

Linda R. Duska, MD, MPH

Professor, Gynecologic Oncology
Vice Chair for Research
Department of Obstetrics and Gynecology
Associate Dean for Clinical Research
University of Virginia School of Medicine
Charlottesville, Virginia

Anne Peters

Anne Peters, MD

Director
USC Clinical Diabetes Programs
Professor of Clinical Medicine
Keck School of Medicine of USC
University of Southern California
Los Angeles, California

Richard E. Pratley

Richard E. Pratley, MD

Samuel E. Crockett Chair in Diabetes Research
Medical Director
AdventHealth Diabetes Institute
Senior Investigator and Diabetes Program Lead
AdventHealth Translational Research Institute
Adjunct Professor of Medicine
Johns Hopkins University School of Medicine 
Orlando, Florida

Lauren Prescott

Lauren Prescott, MD

Assistant Professor, Obstetrics and Gynecology
Division of Gynecologic Oncology
Vanderbilt University Medical Center
Nashville, Tennessee

Ritu Salani

Ritu Salani, MD, MBA

Professor and Division Director
OB/GYN and Gynecologic Oncology
University of California, Los Angeles
Los Angeles, California

Renata R. Urban

Renata R. Urban, MD

Associate Professor
Division of Gynecologic Oncology
Department of Obstetrics & Gynecology
University of Washington School of Medicine
University of Washington Medical Center
Fred Hutchinson/Seattle Cancer Care Alliance
Seattle, Washington

Shannon N. Westin

Shannon N. Westin, MD, MPH

Associate Professor
Division of Surgery
Department of Gynecologic Oncology and Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Robert S. Zimmerman

Robert S. Zimmerman, MD

Vice Chairman
Director, Cleveland Clinic Diabetes Center
Department of Endocrinology
Cleveland Clinic
Cleveland, Ohio

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Novo Nordisk Inc

Target Audience

This program is intended for primary care providers, physicians, nurse practitioners, physician assistants, and the patients with diabetes under their care.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Select appropriate GLP-1 RA therapies for patients with T2D based on their CV risk
  • Select appropriate GLP-1 RA therapies for patients with T2D based on their renal function
  • Select appropriate GLP-1 RA therapies for patients with T2D based on factors such as their glucose control or need for weight loss

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty Disclosure

Primary Author

Martin J Abrahamson, MD, FACP

Associate Professor of Medicine
Harvard Medical School
Director, Division of CME
Department of Medicine
Beth Israel Deaconess Medical Center
Boston, Massachusetts

Martin J. Abrahamson, MD, FACP, has disclosed that he has received consulting fees from AstraZeneca and Novo Nordisk.

Zachary T. Bloomgarden, MD, MACE

Clinical Professor
Division of Endocrinology
Department of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York

Zachary T. Bloomgarden, MD, MACE, has disclosed that he has received consulting fees from AstraZeneca, Boehringer Ingelheim, Merck, Novartis, and Sanofi and has ownership interest in Humana, Johnson & Johnson, and Novartis.

Linda R. Duska, MD, MPH

Professor, Gynecologic Oncology
Vice Chair for Research
Department of Obstetrics and Gynecology
Associate Dean for Clinical Research
University of Virginia School of Medicine
Charlottesville, Virginia

Linda R. Duska, MD, MPH, has no relevant financial relationships to disclose.

Anne Peters, MD

Director
USC Clinical Diabetes Programs
Professor of Clinical Medicine
Keck School of Medicine of USC
University of Southern California
Los Angeles, California

Anne Peters, MD, has disclosed that she has received consulting fees from Abbott Diabetes Care, Boehringer Ingelheim, Lilly, Livongo, MannKind, Merck, Novo Nordisk, Pendulum Therapeutics, and Sanofi; has received funds for research support from Dexcom and vTv Therapeutics; and has ownership interest in Livongo, Mellitus Health, Omada Health, Pendulum Therapeutics, and Stability Health.

Richard E. Pratley, MD

Samuel E. Crockett Chair in Diabetes Research
Medical Director
AdventHealth Diabetes Institute
Senior Investigator and Diabetes Program Lead
AdventHealth Translational Research Institute
Adjunct Professor of Medicine
Johns Hopkins University School of Medicine 
Orlando, Florida

Richard E. Pratley, MD, has disclosed that he has received funds for research support paid to his institution from Lexicon, Ligand, Lilly, Merck, Novo Nordisk, and Sanofi; consulting fees from GlaxoSmithKline, Janssen, Lilly, Merck, Novo Nordisk, and Sanofi; and fees for non-CME/CE services paid to his institution from Novo Nordisk.

Lauren Prescott, MD

Assistant Professor, Obstetrics and Gynecology
Division of Gynecologic Oncology
Vanderbilt University Medical Center
Nashville, Tennessee

Lauren Prescott, MD, has no relevant financial relationships to disclose.

Ritu Salani, MD, MBA

Professor and Division Director
OB/GYN and Gynecologic Oncology
University of California, Los Angeles
Los Angeles, California

Ritu Salani, MD, MBA: consultant/advisor/speaker: GSK, Merck, Regeneron, Seagen.

Renata R. Urban, MD

Associate Professor
Division of Gynecologic Oncology
Department of Obstetrics & Gynecology
University of Washington School of Medicine
University of Washington Medical Center
Fred Hutchinson/Seattle Cancer Care Alliance
Seattle, Washington

Renata R. Urban, MD, has no financial relationships to disclose.

Shannon N. Westin, MD, MPH

Associate Professor
Division of Surgery
Department of Gynecologic Oncology and Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Robert S. Zimmerman, MD

Vice Chairman
Director, Cleveland Clinic Diabetes Center
Department of Endocrinology
Cleveland Clinic
Cleveland, Ohio

Robert Zimmerman, MD, has disclosed that he has received consulting fees from Novo Nordisk; fees for non-CME/CE services from LifeScan and Merck; and funds for research support from Bayer, Merck, and Novo Nordisk.

Staff Disclosure

Staff

Zachary Schwartz, MSc, ELS

Scientific Director

Zachary Schwartz, MSc, has no relevant conflicts of interest to report.

Julie Skowronski, FNP-BC

Julie Skowronski, FNP-BC, has no relevant conflicts of interest to report.

Carolyn Skowronski, PharmD

Associate Director, Scientific Services

Carolyn Skowronski, PharmD, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from February 26, 2020, through February 25, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.

 

Goal


The goal of this ClinicalImpact curriculum is to improve the competence of primary care physicians, nurse practitioners, physician assistants, and other members of the healthcare team in managing type 2 diabetes.